Trial Profile
A randomized Phase II study of vemurafenib plus cobimetinib continuous versus intermittent, in previously untreated BRAFV600- mutation positive patients with unresectable locally advanced or metastatic melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Jun 2021 Primary endpoint has not been met. (Progression Free Survival (PFS), as per Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 14 Feb 2020 Status changed from active, no longer recruiting to completed.